Periodic review of established Complete over-arching Structural Review of funding schemes to determine NHMRC’s grant program by January 2017. strengths and identify improvements can be made. 2016-17 2017-18 2018-19 2019-20 Target Target Target Target Quantitative performance criteria Percentage of Medical Research Endowment Account 50% 50% 50% 50% funding to the NHMRC Project Grant scheme. Percentage of annual research budget awarded to Indigenous >5% >5% >5% >5% health research. Program objective B. Boosting dementia research Dementia is now the second leading cause of death in Australia and no cure exists. The Australian Government, through NHMRC, will tackle the dementia burden through a series of initiatives to: boost Australia’s dementia research capacity; prioritise funding for vital new dementia research projects; and translate research into new treatments and better care for people with dementia. Operating within the NHMRC governance arrangements, the NHMRC National Institute for Dementia Research will lead this effort, drawing together existing activity and developing a strategic research and translation agenda through identifying national research and translation priorities. Qualitative performance criteria 2016-17 Reference point or target Funding provided for large scale Undertake an additional grant round to support research projects in priority areas priority research projects. for dementia. Program objective C. Streamlining assessment and management processes and developing a nationally consistent approach to clinical trials In 2016-17, NHMRC will continue to work collaboratively with States, Territories, other Commonwealth entities, industry, clinical sites and academic stakeholders, towards a nationally consistent approach to the site assessment and authorisation of clinical trials. This approach will expedite the clinical trials review process in both the public and private health sectors, and enable Australian sites to be more competitive internationally. NHMRC will complete pilot studies to implement a streamlined clinical trial site authorisation process and continue the development of a market driven initiative that aims to recognise sites that are willing and able’ to conduct high quality clinical trials. In ‘ready, addition, NHMRC will release an improved ethics application form and will develop contemporary guidance around safety monitoring and reporting requirements for clinical
Periodic review of established funding schemes to determine strengths and identify improvements can be made. Complete over-arching Structural Review of NHMRC’s grant program by January 2017. Quantitative performance criteria 2016-17 Target 2017-18 Target 2018-19 Target 2019-20 Target Percentage of Medical Research Endowment Account funding to the NHMRC Project Grant scheme. 50% 50% 50% 50% Percentage of annual research budget awarded to Indigenous health research. >5% >5% >5% >5% Program objective B. Boosting dementia research Dementia is now the second leading cause of death in Australia and no cure exists. The Australian Government, through NHMRC, will tackle the dementia burden through a series of initiatives to: boost Australia’s dementia research capacity; prioritise funding for vital new dementia research projects; and translate research into new treatments and better care for people with dementia. Operating within the NHMRC governance arrangements, the NHMRC National Institute for Dementia Research will lead this effort, drawing together existing activity and developing a strategic research and translation agenda through identifying national research and translation priorities. Qualitative performance criteria 2016-17 Reference point or target Funding provided for large scale research projects in priority areas for dementia. Undertake an additional grant round to support priority research projects. Program objective C. Streamlining assessment and management processes and developing a nationally consistent approach to clinical trials In 2016-17, NHMRC will continue to work collaboratively with States, Territories, other Commonwealth entities, industry, clinical sites and academic stakeholders, towards a nationally consistent approach to the site assessment and authorisation of clinical trials. This approach will expedite the clinical trials review process in both the public and private health sectors, and enable Australian sites to be more competitive internationally. NHMRC will complete pilot studies to implement a streamlined clinical trial site authorisation process and continue the development of a market driven initiative that aims to recognise sites that are ‘ready, willing and able’ to conduct high quality clinical trials. In addition, NHMRC will release an improved ethics application form and will develop contemporary guidance around safety monitoring and reporting requirements for clinical
2016-17_Health_PBS_4.13_NHMRC.docx